Navigation Links
Stanford discoveries about tumor-suppressing protein could help to reduce treatment side effects
Date:5/12/2011

STANFORD, Calif. Researchers at the Stanford University School of Medicine have untangled two distinct ways in which a common, naturally occurring "tumor-suppressor" protein works. The separation of these two functions which can have quite different consequences could enhance efforts to develop treatment approaches that mitigate the sometimes-devastating side effects of radiotherapy and chemotherapy.

The protein, p53, is mutated or missing in more than half of all human cancers, and most cancers involve at least some compromise in its function.

Cancer is caused by two categories of mutations: those that activate oncogenes, whose protein products drive cells into overzealous replication, and those that disable tumor-suppressor genes, which code for proteins that sense this abnormal behavior and put the brakes on it.

"We knew that p53 responds to two different types of signals: DNA damage and oncogene activity," said Laura Attardi, PhD, associate professor of radiation oncology and of genetics. "We wanted to know if p53 responds to both in the same way." Attardi is senior author of a study to be published May 13 in Cell that throws light on crucial molecular details about how p53 works.

It is widely understood that p53 can temporarily or permanently shut down cell division in response to either acute damage to a cell's DNA or biochemical signals within a cell that suggest it's prone to becoming a cancer cell. In extreme cases, p53 convincingly counsels the cell to commit suicide, thereby preventing the possibility of a tumor arising.

Attardi and her colleagues created bioengineered mice in which various parts of p53 were incapacitated. This allowed them to determine which genes are activated by different parts of the protein, and to show that p53's aggressive DNA-damage response and its gentler tumor-suppression response are separable functions.

"We've determined, for the first time, that the gene exp
'/>"/>

Contact: Ruthann Richter
richter1@stanford.edu
650-725-8047
Stanford University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Stanford research casts sober light on Russias mortality crisis
2. Pitt-Stanford research suggests aimless proteins crucial to disease
3. Stanford researchers discover molecular determinant of cell identity
4. New gene regions identified that predispose people to heart attacks, Stanford scientists say
5. Evidence lacking for widespread use of costly antipsychotic drugs, says Stanford researcher
6. Stanford researchers first to turn normal cells into 3-D cancers in tissue culture dishes
7. Certain cancer therapies success depends on presence of immune cell, Stanford study shows in mice
8. Need a study break to refresh? Maybe not, say Stanford researchers
9. Stanford-led study disproves link between genetic variant, risk of coronary artery disease
10. Wider statin use could be cost-effective preventive measure, Stanford study finds
11. Preventive care poses dilemma for emergency departments, Stanford study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... York, NY (PRWEB) September 22, 2014 ... pain on the side of the hip , which ... bursitis treatment in Manhattan. This treatment is now offered at ... which is also called trochanteric bursitis, occurs when the ... a fluid-filled sac in the hip, between the iliotibial ...
(Date:9/22/2014)... The concept of a whole eye transplant seems ... grant from the U.S. Department of Defense, researchers ... Medicine hope to someday make implantation of an ... eye transplant could be a holy grail for ... of ophthalmology and grant co-recipient with colleagues at ...
(Date:9/22/2014)... New York, US (PRWEB) September 22, 2014 ... Heartbeat Experts’ perspectives on stakeholder management needs for the ... speak with Heartbeat Experts on stakeholder strategies for any ... clinically meaningful points of differentiation within an increasingly crowded ... , The impact of identifying community-based thought ...
(Date:9/22/2014)... Va. (PRWEB) September 22, 2014 ... the nation’s leading nonprofit authority on the ... healthcare information exchange, announced findings from its recent ... Health Plan Identifier (HPID) within electronic transactions adopted ... (HIPAA). WEDI conducted the survey from August 20 ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... a new AS365 N3+ Dauphin, the latest version of ... which is based at Miami Valley Hospital ... air medical transport helicopters. , “We have a lot ... Health Vice President, Emergency, Trauma, and CareFlight. “We’ve been ...
Breaking Medicine News(10 mins):Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Looking ahead: Whole eye transplant under development 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3
... MDAn original and progressive report on health information ... online today, makes ground-breaking recommendations for new ... tensions that currently mar relationships between many HIT ... indemnity and error management of HIT systems. In ...
... November 11, 2010 A new study from researchers in ... more likely to undergo a screening colonoscopy than those who ... for female endoscopists seem to be common among women. In ... notion that rates of screening colonoscopy can be increased by ...
... , THURSDAY, Nov. 11 (HealthDay News) -- U.S. ... to binge-drink, smoke cigarettes or use illicit drugs, a new ... likely to abuse prescription drugs, according to the Center ... from an analysis of 2002 to 2009 data from the ...
... in French . , Montreal, November 11, 2010 ... additional cardiac test when undergoing diagnosis for potential heart problems, ... du Qubec Montral and the Montreal Heart Institute. ... Journal of Cardiopulmonary Rehabilitation and Prevention , a large sample ...
... By Jenifer Goodwin HealthDay Reporter , ... synthetic marijuana known as "K2" is sending young people ... and hallucinations, toxicologists warn. In recent months, physicians ... up in emergency rooms after smoking synthetic marijuana. Despite ...
... chemist Dr Guillaume Lessene has been awarded the Walter and ... annual general meeting in Melbourne, Australia. The $AUD150,000 ... played in shaping the Walter and Eliza Hall Institute. It ... Burgh in August at the age of 94. ...
Cached Medicine News:Health News:Fortify HIT contracts with education and ethics to protect patient safety, say informatics experts 2Health News:Fortify HIT contracts with education and ethics to protect patient safety, say informatics experts 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 2Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 4Health News:Additional cardiac testing vital for patients with anxiety and depression 2Health News:'Fake Marijuana' Users Showing Up in Emergency Rooms 2Health News:'Fake Marijuana' Users Showing Up in Emergency Rooms 3Health News:Medicinal chemist wins inaugural De Burgh Fellowship 2
(Date:9/22/2014)... WASHINGTON and SHANGHAI ... Healthcare Group (BHG), a global knowledge leader in ... strategic partnership to support healthcare innovation in ... for personal connected health technologies. Continua and BHG ... Healthcare Forum being held this week in ...
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, ... therapeutic devices to address infectious disease, cancer and ... Advanced Research Projects Agency (DARPA) has informed the ... to proceed with year four of a five-year ... on September 30, 2011 under DARPA,s Dialysis-Like Therapeutics ...
(Date:9/22/2014)... , Sept. 22, 2014 ... of the "Global Ablation Technologies (Radiofrequency, Ultrasound, ... 2019" report to their offering. ... the global ablation technologies market has been divided ... ultrasound, microwave, cryotherapy, hydrothermal, and hydromechanical ablation technologies. ...
Breaking Medicine Technology:Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3
... 5, 2012  InterMune, Inc. (NASDAQ: ITMN ) ... the fourth quarter ended December 31, 2011, as well ... Esbriet therapy in Germany during 2011.   InterMune ... including new efficacy data from the RECAP extension study ...
... TUCSON, Ariz. and PROVIDENCE, R.I., Jan. 5, 2012 ... it has awarded $1.0 million to Tivorsan Pharmaceuticals ... filing of an Investigational New Drug (IND) application with ... recombinant humanized form of biglycan as a potential muscular ...
Cached Medicine Technology:InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights 2InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights 3InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights 4InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights 5InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights 6InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights 7InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights 8MDA Awards $1 Million to Tivorsan Pharmaceuticals for Accelerating Pivotal Pre-Clinical Work on TVN-102 as a Potential Muscular Dystrophy Treatment 2MDA Awards $1 Million to Tivorsan Pharmaceuticals for Accelerating Pivotal Pre-Clinical Work on TVN-102 as a Potential Muscular Dystrophy Treatment 3MDA Awards $1 Million to Tivorsan Pharmaceuticals for Accelerating Pivotal Pre-Clinical Work on TVN-102 as a Potential Muscular Dystrophy Treatment 4
... For enzyme immunoassays, designed to meet the ... and allows the user to run set ... The floating manifold on this strip washer ... at a time. Reliable, compact, and self-contained, ...
... available to handle multiple assays: ... Embla 384 Cell washer has ... optimized to avoid cell disturbance. ... and have been integrated with ...
... miniGene LW is a new plate washing system ... and 384 channel microplates with flat, V-shaped or ... 8 or 16 channel nozzle heads. Simple LCD ... An optional plate stacker is available for the ...
Space-saving counter top model,User initiated manual defrost,Standard features (see above),Internal freezing compartment,Removable half-shelf in refrigerator,Two shelves in door,UL 471 Commercial Ref...
Medicine Products: